In high-volume equine anthelmintic paste production, the governing risk is not bulk assay recovery but segment-to-segment content uniformity in a filled multi-dose syringe. Oxibendazole (methyl 5-propoxy-1H-benzimidazol-2-ylcarbamate) is placed at 10%–12% w/w in a non-aqueous, water-activity-controlled base consisting of medium-chain triglycerides, fumed silica, hydrogenated castor oil, and a low-moisture polyethylene glycol fraction. This loading yields 500 mg active per 5 g dose increment for a 500 kg horse at 10 mg/kg body weight. Release control follows Ph. Eur. 2.9.40 and USP <905> for uniformity of dosage units, while rheological limits are monitored under Ph. Eur. 2.2.10 with a rotating spindle at 20 °C and 10 rpm; residual solvent levels are constrained by VICH GL18. On a commercial line, a planetary mixer applies vacuum at −0.85 bar to remove entrained air before the wet mass passes through a triple roller mill set to a front roll gap of 25–50 µm, reducing active agglomerates to D90 < 50 µm. Batch-to-batch drift in fumed silica level above 0.3% w/w shifts yield stress outside 200–400 Pa and produces incomplete evacuation from the dial-a-dose syringe. Finished product is a multi-dose oral paste filled into high-density polyethylene dial-a-dose syringes for equine strongyle and ascarid control.

What Limits Dissolution in Low-Solubility Canine Tablet Formulations?

For a 100 mg oxibendazole tablet intended for dogs, the practical formulation problem is that the active is practically insoluble in water at neutral pH, making particle size reduction and disintegrant selection the dominant variables in dissolution rate. The tablet core is designed with 100 mg active in a 320 mg total core mass, equivalent to 31.25% w/w, with croscarmellose sodium at 5.0% w/w, povidone binder at 3.0% w/w, and a microcrystalline cellulose–lactose diluent system. Micronized API with D90 < 30 µm is blended in a high-shear granulator with chopper speed 1,500 rpm; the granulation endpoint is set at 2.5–3.5% w/w moisture, and drying in a fluid-bed dryer uses inlet air at 60 °C with product temperature not exceeding 40 °C. Tableting is performed on a rotary press at 10–16 kN compression force, producing tablets with hardness 60–90 N and friability below 1.0%. Compliance testing includes USP <711> and Ph. Eur. 2.9.3 for dissolution, USP <905> for content uniformity, and USP <701> for disintegration with a limit of 15 min. Observed production failures include punch picking when granulate moisture exceeds 4.0% w/w and capping when compaction force exceeds 18 kN. The terminal dosage form is a round, scored tablet in aluminium–PVC blister packaging for companion-animal anthelmintic administration.

For swine feed premix granules, a distinct regulatory pathway applies because the API is incorporated into medicated feed rather than a finished pharmaceutical dosage form. The premix is standardized at 5.0% w/w oxibendazole on a ground corn cob or lactose monohydrate carrier, then diluted to 0.1% w/w in complete feed to align with a targeted intake of 10 mg/kg body weight per day under veterinary direction. Production falls under Regulation (EU) 2019/4 for medicated feed and, in the United States, 21 CFR 558 for new animal drugs in medicated feeds; feed safety systems are operated under ISO 22000, and residual solvent compliance follows VICH GL18. The granulation step uses a top-spray fluidised-bed process with an aqueous binder solution at spray rate 80–120 g/min, inlet air temperature 65–70 °C, and product temperature held below 45 °C to avoid thermal degradation. Sieve analysis is maintained at 150–850 µm, and bulk density is controlled at 0.45–0.65 g/mL to prevent segregation during pneumatic conveying into feed mills. Cross-contamination control requires a dedicated line or verified cleanout procedure, with residual oxibendazole measured by HPLC-MS/MS and action limit below 1 ppm in subsequent non-medicated batches. The terminal product is a free-flowing, dust-reduced granule premix in multi-wall paper sacks for proportioning into swine complete feed at the feed mill.

When the API Is Processed into Oral Drench Suspensions for Sheep and Cattle

When oxibendazole is formulated as an oral drench suspension, the central manufacturing constraint is crystal sedimentation and dose non-uniformity due to the poor wettability of the micronized active. The suspension is standardized at 10.0% w/v, equivalent to 100 mg/mL, with xanthan gum as a suspending agent, sodium citrate buffer, a non-ionic wetting agent, and a preservative system validated according to Ph. Eur. 5.1.3. Dispersion is performed in a high-shear rotor-stator at 10,000 rpm for 20 min, followed by wet milling through a bead mill loaded with 0.5 mm zirconia beads to achieve D90 < 25 µm. Viscosity is controlled at 150–250 mPa·s at 20 °C to maintain pourability while limiting sedimentation. Release testing includes USP <698> for deliverable volume, Ph. Eur. 2.9.3 for dissolution from the suspended state, and USP <905> for uniformity of dispersed dose. The operational boundary is that prolonged exposure of the suspension to temperatures above 30 °C accelerates particle ripening and shifts particle size distribution beyond the specification. The terminal dosage form is an oral drench suspension in high-density polyethylene bottles with a calibrated dosing chamber for sheep and cattle nematode control.

Injectable Formulation Constraints and Parenteral Manufacturing Boundaries

Injectable formulation constraints for oxibendazole arise from the very low aqueous solubility of the benzimidazole carbamate structure; no compendial monograph for injectable oxibendazole exists in Ph. Eur. or USP, and published data for this specific configuration is limited. A target concentration of 50 mg/mL in a mixed co-solvent system requires co-solvent fractions exceeding 40% v/v, typically propylene glycol combined with glycofurol or dimethylacetamide, at which injection-site tolerance data are sparse and must be generated for each candidate species. Parenteral development must nevertheless comply with USP <1>, USP <71>, USP <85>, Ph. Eur. 2.6.1, and Ph. Eur. 2.6.14. Aseptic processing is required because terminal steam sterilization at 121 °C may degrade the drug in aqueous co-solvent systems; membrane filtration through 0.22 µm PVDF is feasible only if the API is fully dissolved and the co-solvent system does not compromise filter integrity. Terminal product types under this boundary are restricted to parenteral solution or suspension presentations for species-specific veterinary use only where regional approval supports the formulation and safety data package.

Following dry granulation and slugging, oxibendazole capsule blends require tight control of bulk density and flow because the API tends to agglomerate when particle size distribution broadens during storage. A 50 mg active per 250 mg total fill weight formulation corresponds to 20% w/w, with pregelatinized starch as filler, sodium starch glycolate at 4.0% w/w, and magnesium stearate at 0.5% w/w added only in the final 3 min of low-shear V-blending at 15 rpm. The powder mixture is specified with Carr index 18–25 and Hausner ratio 1.20–1.33 before encapsulation. Capsule filling is performed on a tamping-pin machine because the formulation is moderately compressible; weight variation is maintained within ±5% for individual units, and locking force is adjusted to prevent telescoping. Release standards include USP <711> and Ph. Eur. 2.9.3 for dissolution, with sampling points at 15 min, 30 min, and 45 min in 0.1 N HCl containing 0.5% sodium lauryl sulfate. The terminal finished product is a size 2 hydroxypropyl methylcellulose or hard gelatin capsule for companion-animal oral administration, with desiccant required in packaging when ambient relative humidity exceeds 60% during storage.